Skip to content
DataLookout
Start free
Menu

CBGNCT06115603

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 5 entries Show 7 more changesShow less
    • Trial completed
    • Final enrollment: 67 participants (planned 76)
    • Primary completion date changed from estimate of Jul 2026 to Jul 15, 2026
    • Study completion date changed from estimate of Jul 2026 to Jul 30, 2026
    • Eligibility criteria expanded, about 36 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Site details revised
  2. Primary and study completion dates: Dec 2025 to Jul 2026v5
  3. Start date changed from estimate of Nov 14, 2024 to Dec 14, 2024v4
  4. Start date: Jul 15, 2024 to Nov 14, 2024
    • Primary endpoints: 2 to 5
    • Eligibility criteria shortened, about 17 words
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
    • Enrollment target: 30 to 76
    • Primary and study completion dates: Oct 2024 to Dec 2025
    • Start date changed from estimate of Jan 2024 to Jul 15, 2024
    • Primary endpoints revised (2)
    • Study sites: 0 to 1
    • Interventions: Cannabigerol (Dietary Supplement), Placebo (Dietary Supplement) to Cannabigerol (Drug), Placebo (Other)
    • Eligibility criteria expanded, about 109 words
    • Secondary endpoints: 13 to 7
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Sustained Attention to Response Task
Timeframe: 75 minutes post CBG/placebo administration
Trail Making Test-Parts A and B (TMT-A&B)
Timeframe: 75 minutes post CBG/placebo administration
Digit Symbol Substitution Test (DSST)
Timeframe: 75 minutes post CBG/placebo administration
Rey Auditory Verbal Learning Test (AVLT)
Timeframe: 75 minutes post CBG/placebo administration
Iowa Gambling Task (IGT)
Timeframe: 75 minutes post CBG/placebo administration

Secondary (7)

Positive and Negative Affect Scale-Expanded Version
Karolinska Sleepiness Scale
Brief Irritability Test
Numeric Rating Scale (pain)
State-Trait Anxiety Inventory (State Version)
Show 2 moreShow less
Visual Analog Scales
Global Impression of Change

Arms and interventions

CannabigerolActive comparator

1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.

PlaceboPlacebo comparator

1mL of Placebo. Placebo is made in the form of MCT oil.

Drugs: Cannabigerol

Other: Placebo

Sites

1 site in 1 country

  • University of ArkansasFayetteville, Arkansas, United States